Motus GI
Fort Lauderdale
Florida
United States
Tel: 908-996-0239
About Motus GI
Motus GI Holdings, Inc. is a medical technology company dedicated to improving endoscopy outcomes and experiences.
YEAR FOUNDED:
2010
LEADERSHIP:
CEO: Mark Pomeranz
CFO: Andrew Taylor
PRODUCTS:
107 articles about Motus GI
-
Motus GI Reports First Quarter 2021 Financial Results and Provides Corporate Update
5/13/2021
Motus GI Holdings, Inc., a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, reported its financial results for the first quarter ended March 31, 2021, and provided a corporate update.
-
Motus GI Announces Publication of a Pure-Vu System® Cost Effectiveness Analysis in the Journal of Cost Effectiveness and Resource Allocation
5/7/2021
- - - - The article states Pure-Vu System is estimated to provide lifetime saving of $833- $992 per patient when compared to standard of care for outpatient colorectal cancer (CRC) screening and surveillance colonoscopy - - - - The researchers indicated that approximately 25% of 15 million outpatient colonoscopies performed annually in the US, or 3.75 million are inadequately prepped
-
Motus GI Receives FDA Clearance to Market the Pure-Vu® System for Upper GI Endoscopy
4/30/2021
Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for a version of the Pure-Vu® System
-
Motus GI Submits 510(k) Application to FDA for the Pure-Vu System for Upper GI Endoscopy
4/6/2021
Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced it has submitted a 510(k) application to the U.S. Food and Drug Administration (“FDA”) for a version of the Pure-Vu® System
-
Motus GI Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update
3/16/2021
Preparing to submit a 510(k) application to FDA by Q3 2021 for Pure-Vu System indication expansion for Upper GI endoscopies
-
Motus GI Announces First Patient Enrolled in a Pilot Study Using the Pure-Vu® System for Patients with Lower GI Bleeding Being Conducted by a Leading U.S. Medical Center
3/15/2021
Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today the enrollment of the first patient in a pilot study of the Pure-Vu® System.
-
Motus GI to Present Pure-Vu GEN2 System at the Centers for Medicare and Medicaid Services ICD-10 Reimbursement Code Committee MeetingCompany seeking to garner reimbursement for certain procedures utilizing its Pure-Vu System
3/8/2021
Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it will present its request for an ICD-10 code at a Center for Medicare and Medicaid Services (CMS) meeting on March 9 th .
-
Motus GI to Release Fourth Quarter and Full Year 2020 Results and Provide a Business Update on March 16
3/2/2021
Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its fourth quarter and full year 2020 financial results on Tuesday, March 16, 2021, after the market close.
-
Motus GI Announces U.S. Patent for the Pure-Vu® System’s Connectivity with Nearly All Commercial Colonoscopes to Provide Improved Visualization During Colonoscopy
2/24/2021
Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, today announced that the U.S. Patent and Trademark Office (USPTO) has issued patent no. 10,925,466, which is titled,
-
Motus GI Announces Warrant Exercise Agreement Resulting in Expected Gross Proceeds to the Company of up to $11 Million
1/27/2021
Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it has signed a warrant exercise agreement with an existing institutional investor
-
Motus GI Expands Intellectual Property Portfolio with U.S. Patent for the Pure-Vu® System’s Universal Method to Mount on the End of Most Commercial Colonoscopes
1/11/2021
Receives additional EU Patent for the Pure-Vu® System that protects the design of its fecal waste evacuation channels
-
Motus GI Announces Clinical Compendium of Pure-Vu System Patient Case Studies As Reported by Several Leading U.S. Hospitals
12/16/2020
Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that it has collected a series of case studies from several leading U.S. hospitals which highlight the advantages of utilizing its Pure-Vu System to succes
-
Motus GI and Memorial Hermann Hospital Partner to Improve its Colonoscopy Efficiencies
12/2/2020
Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today a collaboration with Dr. Nirav Thosani, Director of Advanced Endoscopy, Memorial Hermann Hospital in Houston, Texas, to incorporate the Company’s Pure-Vu
-
Motus GI Reports Third Quarter 2020 Financial Results and Provides Corporate Update
11/12/2020
Revenue growth reflects rebound of inpatient colonoscopy volumes in Q3 and increased demand for the Pure-Vu system from early adopter hospitals
-
Motus GI and NYU Langone Health Partner to Improve its Inpatient Colonoscopy Management
11/3/2020
Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions to help improve clinical outcomes, is launching a new clinical protocol with NYU Langone Health to incorporate the Company’s Pure-Vu ® GEN2 System (Pure-Vu) with the intention to improve the management of its inpatient colonoscopies. Seth Gross, MD, Director of Clinical Care and Quality in the Division
-
Motus GI to Release Third Quarter 2020 Results and Provide a Business Update on November 12
10/29/2020
Motus GI Holdings, Inc., a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced that the Company will release its third quarter 2020 financial results on Thursday, November 12, 2020, after the market close.
-
Motus GI Hosting Key Opinion Leader Call on Improving Endoscopy Outcomes with the Pure-Vu® System
10/13/2020
Motus GI Holdings, Inc.announced that it will host a key opinion leader call on improving inpatient endoscopy outcomes with the Pure-Vu® system on Friday, October 16, 2020.
-
Motus GI Reports Second Quarter 2020 Financial Results and Provides Corporate Update
8/11/2020
The Pure-Vu® System launched in more than 20 major U.S. hospitals, with new evaluations added during the quarter
-
Motus GI to Release Second Quarter 2020 Results and Provide a Business Update on August 11th
7/21/2020
Motus GI Holdings, Inc. , (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that the Company will release its second quarter 2020 financial results on Tuesday, August 11, 2020, after the market close. Management will host a con
-
Motus GI Launches Mobile App to Provide On-Demand Support and Resources to Hospitals Using the Pure-Vu® System
6/15/2020
Motus GI Holdings, Inc. announced that physicians and hospitals using the Pure-Vu® System will now have on-demand access to a full spectrum of Motus support and educational resources via the new Motus GI mobile app, which was launched.